Overview

Circulating Tumor Cells Market is forecasted to value over USD 13.78 billion by 2027 end and register a CAGR of 16% from the forecast period 2020-2027.

FutureWise Market Research has instantiated a report that provides an intricate analysis of Circulating Tumor Cells Market trends that shall affect the overall market growth. Furthermore, it includes detailed information on the graph of profitability, SWOT analysis, market share and regional proliferation of this business. Moreover, the report offers insights on the current stature of prominent market players in the competitive landscape analysis of this market.
According to the research study conducted by FutureWise research analysts, the Circulating Tumor Cells Market is anticipated to attain substantial growth by the end of the forecast period. The report explains that this business is predicted to register a noteworthy growth rate over the forecast period. This report provides crucial information pertaining to the total valuation that is presently held by this industry and it also lists the segmentation of the market along with the growth opportunities present across this business vertical.

Major players included in the Circulating Tumor Cells Market are :    
• JANSSEN
• QIAGEN（ADNAGEN）
• Acousys Biodevices, Inc
• ApoCell
• Advanced Cell Diagnostics
• Fluxion Biosciences
• Biocept
• Fluidigm
• Epic Sciences
• Clearbridge Biomedics
(Note: The list of the major players will be updated with the latest market scenario and trends)

Circulating Tumor Cells Market Segmentation:

By Technology 

• CTC Detection & Enrichment Methods
• Immunocapture (Label-based)
• Positive Selection
• Negative Selection
• Size-based Separation (Label-free)
• Membrane-based
• Microfluidic-based
• Density-based Separation (Label-free)
• Combined Methods
• CTC Direct Detection Methods
• SERS
• Microscopy
• Others
• CTC Analysis

By Application 

• Clinical/ Liquid Biopsy
• Risk Assessment
• Screening and Monitoring
• Research
• Cancer Stem Cell & Tumorigenesis Research
• Drug/Therapy Development

By Product 

• Kits & Reagents
• Blood Collection Tubes
• Devices or Systems

By Specimen 

• Blood
• Bone Marrow

By Region
• North America
• Europe
• Asia-Pacific
• Rest of the world

Competitive Landscape:
• Tier 1 players- established companies in the market with a major market share  
• Tier 2 players
• Emerging players which are growing rapidly
• New Entrants

FutureWise Key Takeaways:
• Growth prospects
• SWOT analysis
• Key trends
• Key data-points affecting market growth

Objectives of the Study:
• To provide with an exhaustive analysis on the Circulating Tumor Cells Market by technology, by application, by product, by specimen and by region
• To cater comprehensive information on factors impacting market growth (drivers, restraints, opportunities, and industry-specific restraints)
• To evaluate and forecast micro-markets and the overall market
• To predict the market size, in key regions— North America, Europe, Asia Pacific and rest of the world
• To record and evaluate competitive landscape mapping- product launches, technological advancements, mergers and expansions

Flexible Delivery Model:
• We have a flexible delivery model and you can suggest changes in the scope/table of content as per your requirement
• The customization services offered are free of charge with purchase of any license of the report.
• You can directly share your requirements/changes to the current table of content to: sales@futurewiseresearch.com

Table of Contents

1. Market Introduction

        1.1. Objectives of the Study 

        1.2. Market Definition 

        1.3. Market Scope 

               1.3.1. Years Considered for the Study

               1.3.2. Market Covered

        1.4. Currency 

        1.5. Limitations 

        1.6. Stakeholders 

 2.  Research Methodology 

        2.1. Research Data 
              2.1.1. Secondary Data
                          2.1.1.1. Key Data from Secondary Sources
              2.1.2. Primary Data

         2.1.2.1. Key Data from Primary Sources

        2.2. Market Size Estimation 
        2.3. Market Breakdown and Data Triangulation 

        2.4. Assumptions for the Study  

3. Executive Summary

        3.1. Market Outlook
        3.2. Segment Outlook
        3.3. Competitive Insights

4. Global Circulating Tumor Cells Market Variables, Trends & Scope

        4.1. Market Lineage Outlook

        4.2. Penetration and Growth Prospect Mapping

        4.3. Industry Value Chain Analysis

        4.4. Cost Analysis Breakdown

        4.5. Technology Overview

        4.6. Regulatory Framework
                 4.6.1. Reimbursement Framework
                 4.6.2. Standards and Compliances

5. Global Circulating Tumor Cells Market Overview

        5.1. Market Dynamics
                  5.1.1. Market Driver Analysis
                            5.1.1.1. Increasing focus of Circulating Tumor Cells Companies on Brand Protection
                            5.1.1.2. Untapped Opportunities in Emerging Regions
                  5.1.2. Market Restraint Analysis
                            5.1.2.1. High Cost Associated with Implementation of Predictive Analysis
                  5.1.3. Industry Challenges
                            5.1.3.1. Presence of Ambiguous Regulatory Framework

6. Global Circulating Tumor Cells Market Analysis Tools
        6.1. Industry Analysis - Porter’s
               6.1.1. Supplier Power
               6.1.2. Buyer Power
               6.1.3. Substitution Threat
               6.1.4. Threat from New Entrants
               6.1.5. Competitive Rivalry
        6.2. Pestel Analysis
               6.2.1. Political Landscape
               6.2.2. Environmental Landscape
               6.2.3. Social Landscape
               6.2.4. Technology Landscape
               6.2.5. Legal Landscape
        6.3. Major Deals And Strategic Alliances Analysis
                6.3.1. Joint Ventures
                6.3.2. Mergers and Acquisitions
                6.3.3. Licensing and Partnership
                6.3.4. Technology Collaborations
                6.3.5. Strategic Divestments
        6.4. Market Entry Strategies
        6.5. Case Studies

7. Global Circulating Tumor Cells Market, By Technology Historical Analysis and Forecast 2020-2027 (USD Million)

        7.1 CTC Detection & Enrichment Methods

                7.1.1. Immunocapture (Label-based)

                            7.1.1.1. Positive Selection

                            7.1.1.2. Negative Selection

                7.1.2. Size-based Separation (Label-free)

                            7.1.2.1. Membrane-based

                            7.1.2.2. Microfluidic-based

                7.1.3. Density-based Separation (Label-free)

                7.1.4. Combined Methods

        7.2 CTC Direct Detection Methods

                7.2.1. SERS

                7.2.2. Microscopy

                7.2.3. Others

        7.3 CTC Analysis

8. Global Circulating Tumor Cells Market, By Application Historical Analysis and Forecast 2020-2027 (USD Million)

        8.1. Clinical/ Liquid Biopsy

                8.1.1. Risk Assessment

                8.1.2. Screening and Monitoring

        8.2.Research

                8.2.1. Cancer Stem Cell & Tumorigenesis Research

                8.2.2. Drug/Therapy Development

9. Global Circulating Tumor Cells Market, By Product Historical Analysis and Forecast 2020-2027 (USD Million)

        9.1. Kits & Reagents

        9.2. Blood Collection Tubes

        9.2. Devices or Systems

10. Global Circulating Tumor Cells Market, By Specimen Historical Analysis and Forecast 2020-2027 (USD Million)

        10.1. Blood  
        10.2. Bone Marrow

11. North America Market Analysis 2015–2019 and Forecast 2020–2027 (USD Million)

        11.1. Introduction

        11.2. Historical Market Size (USD Million) Analysis By Country, 2015-2019

                  11.2.1. U.S.A

                  11.2.2. Canada

                  11.2.3. Mexico

        11.3. Market Size (USD Million) Forecast for North America 2020-2027 

12. Latin America Market Analysis 2015–2019 and Forecast 2020–2027 (USD Million)

        12.1. Introduction

        12.2. Historical Market Size (USD Million) Analysis By Country, 2015-2019

                 12.2.1. Brazil

                 12.2.2. Venezuela

                 12.2.3. Argentina

                 12.2.4. Rest of Latin America

        12.3. Market Size (USD Million) Forecast for Latin America 2020-2027  

13. Europe Market Analysis 2015–2019 and Forecast 2020–2027 (USD Million)

        13.1. Introduction

        13.2. Historical Market Size (USD Million) Analysis By Country, 2015-2019

                  13.2.1. Germany

                  13.2.2. U.K

                  13.2.3. France

                  13.2.4. Italy

                  13.2.5. Spain

                  13.2.6. Russia

                  13.2.7. Poland

                  13.2.8. Rest of Europe

        13.3. Market Size (USD Million) Forecast for Europe 2020-2027

14. Asia Pacific Market Analysis 2015–2019 and Forecast 2020–2027 (USD Million)

        14.1. Introduction

        14.2. Historical Market Size (USD Million) Analysis By Country, 2015-2019

                  14.2.1. Japan

                  14.2.2. China

                  14.2.3. India

                  14.2.4. Australia and New Zealand

                  14.2.5. ASEAN

                  14.2.6. Rest of Asia Pacific

        14.3. Market Size (USD Million) Forecast for Asia Pacific 2020-2027

15. Middle East and Africa Market Analysis 2015–2019 and Forecast 2020–2027 (USD Million)

        15.1. Introduction

        15.2. Historical Market Size (USD Million) Analysis By Country, 2015-2019

                  15.2.1. Saudi Arabia

                  15.2.2. UAE

                  15.2.3. South Africa

                  15.2.4. Egypt

        15.3. Market Size (USD Million) Forecast for MEA 2020-2027           

16. Company Profiles (Competition Dashboard, Competitors Deep Dive, Product Connected Devices and Disease Indication Portfolio, Financial Layouts)

    16.1 JANSSEN

            16.1.1. Company Overview (HQ, Business Segments, Employee Strength)

            16.1.2. Product Portfolio

            16.1.3. SWOT Analysis

            16.1.4. Financial Overview

            16.1.5. Strategic Overview

    16.2 QIAGEN（ADNAGEN）

            16.2.1. Company Overview (HQ, Business Segments, Employee Strength)

            16.2.2. Product Portfolio

            16.2.3. SWOT Analysis

            16.2.4. Financial Overview

            16.2.5. Strategic Overview

    16.3 Acousys Biodevices, Inc

            16.3.1. Company Overview (HQ, Business Segments, Employee Strength)

            16.3.2. Product Portfolio

            16.3.3. SWOT Analysis

            16.3.4. Financial Overview

            16.3.5. Strategic Overview

    16.4 ApoCell

            16.4.1. Company Overview (HQ, Business Segments, Employee Strength)

            16.4.2. Product Portfolio

            16.4.3. SWOT Analysis

            16.4.4. Financial Overview

            16.4.5. Strategic Overview

    16.5 Advanced Cell Diagnostics

            16.5.1. Company Overview (HQ, Business Segments, Employee Strength)

            16.5.2. Product Portfolio

            16.5.3. SWOT Analysis

            16.5.4. Financial Overview

            16.5.5. Strategic Overview

    16.6 Fluxion Biosciences

            16.6.1. Company Overview (HQ, Business Segments, Employee Strength)

            16.6.2. Product Portfolio

            16.6.3. SWOT Analysis

            16.6.4. Financial Overview

            16.6.5. Strategic Overview

    16.7 Biocept

            16.7.1. Company Overview (HQ, Business Segments, Employee Strength)

            16.7.2. Product Portfolio

            16.7.3. SWOT Analysis

            16.7.4. Financial Overview

            16.7.5. Strategic Overview
    16.8 Fluidigm

            16.8.1. Company Overview (HQ, Business Segments, Employee Strength)

            16.8.2. Product Portfolio

            16.8.3. SWOT Analysis

            16.8.4. Financial Overview

            16.8.5. Strategic Overview

    16.9 Epic Sciences

            16.9.1. Company Overview (HQ, Business Segments, Employee Strength)

            16.9.2. Product Portfolio

            16.9.3. SWOT Analysis

            16.9.4. Financial Overview

            16.9.5. Strategic Overview

    16.10 Clearbridge Biomedics

            16.10.1. Company Overview (HQ, Business Segments, Employee Strength)

            16.10.2. Product Portfolio

            16.10.3. SWOT Analysis

            16.10.4. Financial Overview

            16.10.5. Strategic Overview

17. FutureWise SME Key Takeaway Points for Client

Tables

Figures